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CHAPTER I 
 
                       BIOISOSTERES AND SUBSTITUTIONS 
 
 
 The drug discovery and approval process are extremely costly and time 
consuming.  The expenses associated with FDA approval are approaching 1.5 billion 
dollars, which has impacted the way in which pharmaceutical companies approach 
problems.  New lead molecular entities are run through a gauntlet of in vitro, in vivo, and 
in silico tests to determine their suitability for human use prior to undertaking any clinical 
trials.  Currently most of the drug failures are related to poor pharmacokinetic or toxicity 
problems, which have been discovered in the late stages of clinical trials.  It would be 
much more preferable from an economic standpoint if drug candidates doomed to fail 
ultimately in clinical trials can be identified in the earlier stages of drug discovery.  
Rarely does a drug come to market without extensive modifications having been made to 
the original lead molecular structure. More often than not, the drug has undergone a 
series of systematic modifications designed to improve any known pharmacologic and/or 
toxic deficiencies that have been detected in laboratory and animal model studies. 
Sometimes these modifications are minor, and other times, there may be so many 
changes that a completely new compound has emerged that seemingly has little or no 
similarity to the original lead.
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For those lead compounds that do show promise, experimentalists will often make 
small changes to improve the necessary list of characteristics that are necessary for 
improved efficacy and pharmacokinetic patterns. These small incremental changes and 
subsequent biological testing are the basis for structure-activity relationships, which 
provide drug discovery scientists with information about what molecular features 
enhance or decrease biological activity.  Most commonly, medicinal chemists focus on 
systematically modifying one part of a potential drug candidate, while leaving the rest of 
the structure unmodified.  Such approaches have yielded commercially successful drug 
therapies.  Perhaps the most highly acclaimed example of such systematic modifications 
based on physical organic chemistry is cimetidine, which is used for the treatment of 
stomach ulcers and related gastrointestinal disorders.  Cimetidine was the first billion 
dollar selling medicine.  It is not unusual for pharmaceutical laboratories to replace 
hundreds of substituents in an attempt to find the most effective structure.  The basis for 
many of these changes include historical precedent, ease of synthesis, information 
gleaned from structural studies, and physicochemical reasons. To find the right 
substituent, researchers have often invoked the idea of bioisosteres. 
Bioisosteres are substituents that are similar in their chemical and/or physical 
properties, and they achieve comparable biological functionality. Bioisosteres are 
classified into two categories: classical and non-classical bioisosteres. Classical 
bioisosteres are frequently similar in size (although it is not absolutely necessary in all 
cases), so they may be added to a lead structure without in general causing any new, 
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unfavorable internal steric interactions and more importantly without interfering with 
drug-receptor binding. An example of a bioisosteric replacement would be uracil and 5-
fluorouracil. The two molecules are identical with the exception of a hydrogen atom that 
has been replaced by a fluorine atom at the double bonded carbon of the ring structure. 
The atomic radius of the fluorine atom is similar in size to a hydrogen atom, but there is a 
completely different electronic environment created.  Such a substitution, fluorine for 
hydrogen, may serve to provide a new favorable electrostatic interaction with the receptor 
(a pharmacodynamics effect), or it may serve to provide a metabolic blocker (a 
pharmacokinetic effect).  In the specific case of 5-fluorouracil, the fluorine-hydrogen 
substitution results in a mechanism-based inactivator.  
Clearly in the case of the substitution of a hydrogen with a fluorine the difference 
in the electronegativity has the potential for a significant impact.  Although 5-fluorouracil 
is similar in shape to uracil, the chemistry and pharmacology of the two drugs provide a 
different enzymatic outcome.  In the case of uracil, the natural mechanistic pathway 
associated with thymidine synthase is removal of a proton.  When the proton has been 
replaced with a fluorine, a suicide substrate inhibitor has been created because the 
fluorine, the most electronegative element, cannot leave as a positively charged ion (as is 
the case with a hydrogen in that position of the ring) which is a requirement for the 
biochemical transformation. This simple substitution that produces 5-fluorouracil 
generates a drug that is able to inhibit RNA replication enzymes, which helps prevent the 
growth of cancerous cells.1.  
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Figure 1. A side-by-side comparison of the natural substrate (uracil, 1) for 
thymidate synthase and the anticancer drug 5-fluorouracil. 
 
It should be noted, that the programming language used for the development of 
the “rule”-based transformations outlined in this thesis automatically replaces Kekule 
structures with ring structures.  For example, the single Kekule strcuture of benzene on 
the left in Figure 2 would be displayed only as the structure on the right.  This is even 
true for molecular systems that may not be classically considered as aromatic, which is 
the case in Figure 1.   
 
       
 
Figure 2. A comparison of aromatic structures of benzene. 
 
 
Another example of a classical bioisostere is found in comparing procainamide 
and procaine. When comparing the structures of procaine and procainamide, it is clear 
that the only substitution between these two compounds is a nitrogen atom replacement 
of an oxygen atom (i.e., an ester functional group has been replaced by an amide). It 
should be noted that the arrow in Figure 3 and throughout this thesis are not implying 
necessarily that there is a single chemical transformation to convert one structure into 
another.  Rather, the arrows displayed are depicting an in silico transformation that yields 
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another potential lead structure.  Therefore, these reaction arrows are not connecting 
reactants to products, but original structures to new structures that should be considered 
as potential leads.  While this substitution in Figure 3 may not seem significant, there is a 
dramatic difference in reactivity due to electronic differences.  Esters hydrolysis occurs 
more readily than amide hydrolysis.  The change from ester to amide has resulted in the 
creation of a drug that has been used in the treatment of cardiac arrhythmias for over 
sixty years.2 Again, it should be noted that an actual chemical transformation converting 
an ester to an amide is not what is meant in Figure 3.  What is being shown is the 
comparison of two similar molecular structures which typically must be prepared 
synthetically by two different routes.  
              
                Figure 3. Procaine to procainamide transformation. 
 
 
Classical bioisosteres are generally ring equivalent structures, covalent atoms, or 
functional groups. Non-classical bioisosteres do not follow the same patterns as classical 
bioisosteres. While they could have the same number of atoms, their abilities to substitute 
are based upon characteristics such as electronic properties, spatial arrangements, 
physicochemical properties, or functions that are critical in biological activites3.  The 
biological activity is the ultimate test for non-classical bioisosteres.  A tetrazole moiety 
would be an ideal non-classical bioisosteric replacement for a carboxylate.4While the 
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structures of these two groups are vastly dissimilar from an atomic functional group 
perspective, their overall steric and electrostatic properties are quite similar from the 
perspective of drug-receptor interactions.  This similarity for drug-receptor interactions 
leads to equivalent or enhanced biological activity.  Thus, the tetrazole moiety often can 
be substituted for the carboxylate functional group.  This isosteric replacement has been 
used effectively in the angiotensin building antagonists (e.g. losartan and irbesartan).  
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            CHAPTER II 
 
SMILES AND SMIRKS: THE DRUG GURU PROJECT 
 
 
Historically, beginning with the work of Paul Ehrlich, pharmaceutical scientists 
have used a systematic trial-and-error approach in new discoveries.  Before the advent of 
recent technologies, many of these scientists worked independently, or in small groups, in 
developing new compounds and treatments, with little or no knowledge of the work of 
their contemporaries. They relied upon print publications and word of mouth to keep 
informed. Many chemists have spent a great deal of time working with promising lead 
compounds that have not resulted in viable drug candidates because potential drug 
modifications were ignored or overlooked. In many other cases, a new discovery could 
have been made with a slight modification of the drug structure.  
Drug discovery demands a collaborative environment traditionally within a 
proprietary corporate research setting.  As computer technology advanced in the latter 
part of the twentieth century, it has become much easier for researchers to work in 
different laboratories in different parts of the world to collaborate and share ideas. 
Chemists can share documents, experimental designs, and results within minutes of 
completion. Previously, other researchers would only be able to see these same results 
after reading them in a publication. But, even technology, however, has its limits. While 
chemists can share information, it would only be shared if the right people knew who 
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to speak with and where similar research was being conducted. Near the end of the 
twentieth century, scientists began to seek a way to make this happen. 
In the late 1980’s, chemist David Weininger and his associates designed a 
computer program called SMILES (Simplified Molecular Input Line Entry System).  
SMILES is a software program that utilizes a series of codes that replace letters and 
symbols for the elements and bonds. The coding is based upon the American Standard 
Code for Information Interchange (ASCII). Manipulation of this coding allows for 
accurate representation of elements, bonding, aromaticity, branching, stereochemistry, 
and isotopes. By using Structure Diagram Generation algorithms, two dimensional 
figures can be created that show graphical representations of the compounds shown.  
The Drug Guru project was developed at Abbott Laboratories (now AbbVie) to 
assist medicinal chemists with the development of novel lead structures. This clever and 
useful approach utilized SMILES coding. Dr. Kent Stewart (AbbVie) developed a 
computer program in the mid 2000’s that was designed to provide Abbott researchers 
with an opportunity to benefit directly from the efforts of other scientists, even without an 
active collaboration.6 The central role was to develop a set of rules that could generate a 
series of novel lead structures based on the success stories of other drug discovery 
projects.  Experienced medicinal chemists know many of the transformations that can be 
incorporated into a computer code “rules of thumb” using the SMILES language (e.g., the 
conversion of an ester to an amide, the conversion of a hydroxy to methoxy group, etc.)7 
The Drug Guru program takes these transformations and converts them to a web-based 
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application that utilizes computer codes to represent each transformation. These “rules” 
are represented as SMILES code (and SMIRKS, which is based upon the SMILES 
platform, although the name “SMIRKS” is used only because of its similarity to 
“SMILES” and isn’t actually an acronym).8 When a “rule” has been deemed generally 
useful, it is entered into the program and stored for future applications for lead structures 
possessing the potential functional group or molecular structure transformations.  A 
“rule” does not guarantee that the new structure will have biological activity or is even 
appropriate for the specific case, but it is a possibility that should be considered.  Drug 
discovery scientists are looking routinely to develop new biologically active compounds 
based on a current lead. An automated system for structure generation built on a database 
of transformations is an excellent starting point. This is a tremendous resource for a 
medicinal chemist with limited experience.  Even experienced medicinal chemists, 
however, should be able to benefit from an automated program of this type inasmuch as 
they may overlook possible families of compounds.  Moreover, such an approach may be 
extremely beneficial in circumventing patent protection issues for existing drugs. 
In 2006 there were 186 general rules in the Drug Guru system. Of these rules, 133 
were functional group transformations (e.g., 18 amide transformations), and the 
remaining 53 were molecular framework modifications (e.g., 14 ring break 
transformations). The typical input search at that time yielded between 50-150 output 
structures. The size of the input structure was important. Smaller organic molecules will 
yield fewer output structures in general, while larger more complex molecules will 
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provide many more options for output structures. Obviously, as the size of the lead 
molecule increases, there are more possibilities for the application of the transformation 
rules. Admittedly, experienced medicinal chemists already know many, if not all, of the 
fundamental rules. As mentioned above, Drug Guru is more of a reminder to these 
chemists particularly as more rules are added to the database that represent less known 
transformations.  Previously researchers at Abbott Laboratories have identified a large 
number of these transformations since the development of the software in 2006. The 
current version (as of 2011) lists 530 transformations.7 Despite this progress, there are 
many thousands of transformations that have yet to be identified and put into the 
SMILES and SMIRKS coding for Drug Guru.
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                CHAPTER III 
 
                                                                        LIMITATIONS 
 
 
 As with any other scientific method, there are limitations to this type of  
informatics approach for lead development. One of the major criticisms is that it not an 
artificial intelligence program. While a transformation might be perfectly suitable in one 
research project, it may not apply in another. The transformations do not recognize this 
problem. The software will apply whatever rules have been programmed into the system 
and generate new structures accordingly, regardless of the target system being explored. 
While it will recognize problems with bonding, aromaticity, and charges, it will not 
identify specific issues with impracticality, conformational preferences, and energy 
differences. So, it cannot be a substitute for the “common sense” of the researcher nor 
can this approach be considered a structure-based drug design approach. The chemist 
must exercise caution when reviewing the output structures based on this rule-based 
system. In developing the cheminformatics rules, one has to be careful to check the 
results for unintended consequences, which are molecular structures that are chemically 
incorrect (i.e., nonsensical structures).  This can easily happen for generalized rules even 
if the rules have been checked thoroughly. 
Some medicinal chemistry researchers have complained that there are too many 
new structures produced, while others have lamented that not enough diverse possibilities
12 
 
 
have been generated. The chemists who have complained about too many potential leads 
have voiced their concerns that the sheer volume of possibilities is overwhelming. In 
some “rules of thumb” cases, there are indeed literally hundreds of known substitutions. 
There is also no ranking scheme based on some penalty function, so a chemist may have 
to sift through dozens of suggestions to determine which one is the best by inspection.  
Algorithms have yet to be developed in this context that will allow the suggestions to be 
ranked, although future plans in the Bowen group are to develop such penalty functions. 
The chemists who have complained about a lack of quantity, generally have 
worked with compounds that have very few known substitutions or have had little 
research published on the subject. It can be quite frustrating to enter the information for 
the compound and get only one or two output structures. In the worst case scenarios, 
there are no substitutions offered. The value of the system to these researchers is limited.  
In the case of Drug Guru another criticism has emerged about the user 
friendliness of the software. While the SMILES and SMIRKS codes make sense, the 
software itself may be cumbersome and difficult to maneuver. If the chemist understands 
the SMILES and SMIRKS codes, but cannot navigate the software platform to use these 
codes, the program becomes useless. Countless error messages and technical jargon 
problems can convince many to avoid the use of this method. Many chemists would 
rather fight their battles in the laboratory where they have extensive knowledge, rather 
than fight with a computer.  This means that any software designed must take into 
account not only the functionality required but the computer skills of the intended user – 
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the bench chemist involved in medicinal chemistry synthesis, who may or may not have 
the computer programming skills necessary to navigate a complex cheminformatics 
program. 
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             CHAPTER IV 
 
                                                       A NEW SOFTWARE PROGRAM  
 
 
 The Drug Guru code is proprietary, and a decision was made at Abbott not to  
release it to the public. A new software program utilizing a similar rule-based strategy is 
being developed by the Bowen research group in the Center for Drug Design at Mercer 
University College of Pharmacy. The premise of the software program is simple. As 
researchers design new compounds for drug design, they frequently encounter stumbling 
blocks. These stumbling blocks may include side effects, insufficient or overabundant 
inhibition, binding specificity, reaction specificity, rate acceleration, lipophilicity effects, 
steric effects, enzyme inactivation, and electrostatic binding among the many problems 
that may be encountered. In testing, a new compound might show promising biological 
activity, but needs one or more minor modifications to be successful. The new software 
program will allow chemists to have an easier time with these modifications by 
suggesting proven substitutions. Presently there is no ranking scheme to prioritize the 
ranking structures, and these substitutions are not target specific. As the software 
continues to be developed, many of these concerns presumably will be addressed. 
 As mentioned previously, the concept of making substitutions is not new. A 
replacement of a small molecule with another small molecule has been the way drug 
discovery has historically worked. In the past, however, if a researcher had an issue with
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a particular compound, the only way to decide on a good substitution was either trial-and-
error hunches, or to rely on the expertise of the medicinal chemist who could apply 
knowledge-based decisions from experiences, precedents, and/or algorithms (e.g., 
Topless schemes).  Ideally, if the knowledge of many experienced medicinal chemists 
could be distilled into a computer algorithm, then there would be a wealth of information 
available for anyone who used the software. This novel informatics approach provides 
the chemist with an established database of substitutions that have been successful in 
drug discovery case histories.  So while a medicinal chemist may have an exceptional 
command of the drug discovery literature, a well-developed set of “rule-based’ 
transformations will aid in the development of potential novel leads.  If a researcher 
wanted to modify a particular part of a compound with new functional groups or make 
ring system alterations, he/she could simply input their compound into the new program 
and a list of suggested substitutions would be generated. For the veteran medicinal, some 
of these substitutions would be obvious, while others might be more obscure or simply 
overlooked. After the output list of structures is generated, they can be ranked according 
to other criteria (e.g., logP, Lipinski’s Rules of Five, etc.). A review of the list of 
generated molecular structures should be undertaken to see if any make sense from a 
pharmacologic standpoint.  No information about the synthesis of potential compounds 
would be provided because the set of transformation rules are not designed for this 
purpose.  The transformations simply generate new molecular structures based on 
historical precedent and are not target specific. Obviously, not every substitution will 
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work in every situation. The database of rules has no way of “knowing” exactly what the 
researcher’s intent might be. It merely provides a list of possibilities based on previous 
successful examples. Nevertheless, with that said, by providing these in silico generated 
possibilities, there is the potential to provide new leads for a project as well as reduce the 
time and expenses involved.  One overlooked compound could be the difference between 
a successful drug candidate and the project being abandoned. A number of the output 
structures could be rejected for a variety of scientific and/or economic reasons. The 
success of a drug discovery project could rest on an obscure substitution. More often than 
not, the bioisosteres that have been studied are non-classical in nature. As research 
continues, the classical bioisosteres are mostly the ‘rules of thumb’, and the non-classical 
bioisosteres are the basis of new discovery. 
 One of the goals of this research project is to have 50-150 output structures for 
each input structure. For Drug Guru this number of output structures was achieved with 
only 530 rules in place. In just a short period of time, the Bowen research group has 
created a large set of rules that are generally applicable in drug discovery.  Since we do 
not have access to the propriety code at AbbVie, assuming that our new rules are not 
already present in Drug Guru, this would increase that number of output structures by 
nearly 30%. With realistic projections, it would not be unreasonable within a short time 
that the Bowen research group would be able to double the 530 rules that were in place in 
2011. With continued development, it is not unreasonable to expect that the rules could 
number in the thousands within a few short years. Such advances would make the new 
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program an increasingly valuable resource for the bench chemist, who would benefit the 
most from an easy to use program. 
 How is the database of transformations created? Like essentially everything else, 
the database is constructed on foundational principles. There are a few tried and true 
“rules of thumb” that serve as the building blocks of the database (some of these were 
discussed in the “Bioisosteres and Substitutions” section). The majority of the database is 
based on a careful evaluation of successful case studies found in the scientific literature. 
Each year, hundreds of research articles are published detailing successes and failures in 
laboratories from around the world. In a number of these publications and/or disclosures, 
substitutions have been made to improve pharmacokinetic and/or pharmacodynamics 
properties of a particular drug. For years, the Bowen research group has been 
meticulously screening data presented in publications and patents to identify the most 
general lead to drug transformations. When a substitution or modification has been made, 
the specifics of the transformation have been incorporated into SMILES and SMIRKS 
codes within the framework of the software program.     
For the work of this thesis, the critical evaluation of the literature has been the 
most time consuming respect of the research. Typically, a monthly or bimonthly research 
journal may have anywhere between 20 and 50 research articles. While the abstracts can 
provide some basic information, they frequently do not go into depth about the 
substitutions that were made. In order to understand the physicochemical properties and 
biological activities that have been reported, each article must be analyzed. Such careful 
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reviews require substantial time investments, with no guarantee of finding anything that 
fits the criterion of the software. Additionally, when a suitable substitution has been 
identified, the SMILES and SMIRKS codes must be produced. There are some 
commercially available software programs that do assist in this endeavor, but they have 
limitations. In most cases, the code is constructed through trial-and-error methods with 
rigorous quality control checking. Just as a single bond or atom can wreak havoc on an 
otherwise stable molecule, a single misplaced symbol can mean success or failure in 
coding. Some codes are put together in literally seconds. In other cases, it takes several 
hours to get just the right framework to make the SMILES and SMIRKS codes 
meaningful for the desired transformation in a variety of chemical environments. The 
biggest challenge is making sure that there are no unintended consequences where 
modifications are made that lead to unrealistic structures.  Chemistry drawing programs 
offer SMILES codes for structures input and export, but these codes are not always 
compatible with SMIRKS codes.  Interestingly, the SMILES codes from one program are 
not always compatible with another, so this code porting issue creates additional 
frustrating obstacles. However, as research has continued over the past few years, the 
learning curve has been surmounted: the coding time has decreased, as practice and 
problem solving experiences have helped overcome prior frustrations and failures.  
The final section of this thesis is devoted to the development of the 
cheminformatics rules that may be used in drug design. There are a large number of 
research articles referenced, with over two hundred SMILES and SMIRKS codes (along 
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with figures of each substituted portion). Approximately three thousand research articles 
were reviewed to select sufficiently general rules.  It is not the intent of this thesis to 
present in detail the background and context for each transformation.  The purpose of this 
thesis, however, is to provide some general transformation rules that have led to 
increased biological activities and are structurally interesting.  These new rules should 
become part of the new database of transformations. 
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          CHAPTER V 
 
                              RESEARCH AND RESEARCH APPROACHES 
 
 
Over the past few years, ongoing efforts in the Bowen lab have resulted in 
mastering a number of basic rules for Drug Guru and our in-house software. The 
transformations include 19 catechol transformations (“transformation” meaning in this 
case, a bioisosteric substitution), 17 carboxylate transformations, 7 aldehyde 
transformations, 10 amide transformations, 9 ester transformations, 8 ketone 
transformations, 3 thioether transformations, 3 thiourea transformations, and a number of 
others. These were important fundamental rules that will be important for the long term 
success of the program. A number of these substitutions are well known functional group 
replacement strategies (e.g., converting an ester to an amide or an inverse amide). Quite a 
few of the most fundamental transformations are detailed in Richard B. Silverman’s 
textbook The Organic Chemistry of Drug Design and Drug Action.9 These rules are the 
foundations of the system. Some selected examples of these well-known modifications 
are shown below. Each example shows the substitution of a hydroxyl group with some 
other functional group previously used in medicinal chemistry research. The boxes in the 
figures indicate the bonding points. 
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Figure 4. A hydroxyl group replacement with a methylhydroxyl group. The SMIRKS 
code for this substitution: CO>>CC 
 
 
                     
 
Figure 5. A hydroxyl group replacement with a 1-methylurea. The SMIRKS code for 
this transformation: CO>>CNC(=O)N. 
 
   
                       
 
Figure 6. A hydroxyl group replacement with N-methylmethanediamine. The 
SMIRKS code for this transformation: CO>>CNCN. 
 
 
                                          
 
Figure 7. A hydroxyl group replacement with 2-methyl-1,3-propanediamine.The 
SMIRKS for this transformation: CO>>CC(CN)CN. 
 
 
The following are some additional transformations showing “rules of thumb” from the  
 
Silverman text:
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Basic transformations (using SMIRKS codes) 
 
 
                                                       
 
Figure 8. Benzene ring replacement with a pyridine ring. The SMIRKS code for this                   
transformation: c1ccccc1>>c1ccccn1. 
 
 
                                                      
 
Figure 9. Benzene ring replacement with a pyrimidine ring. The SMIRKS code for 
this transformation: c1ccccc1>>c1ncncc1. 
 
 
                                                           
     
Figure 10. Benzene ring replacement with a ring-contracted polythiophene aromatic    
heterocycle.  The SMIRKS code for this transformation: c1ccccc1>>c1sccc1. 
 
 
                                                     
 
Figure 11. Benzene ring replacement with a ring-contracted thiazole aromatic 
heterocycle. The SMIRKS code is: c1ccccc1>>c1cscn1. 
 
 
                                                     
 
Figure 12. Benzene ring replacement with a ring-contracted furan aromatic 
heterocycle.  The SMIRKS code is: c1ccccc1>>c1cocc1. 
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Figure 13. Benzene ring replacement with a ring-contracted isoxazole aromatic 
heterocycle. The SMIRKS code is: c1ccccc1>>c1conc1. 
 
 
                                                       
                                       
Figure 14. Carbonyl functional group replacement to dimethylsulfoxide group. The 
SMIRKS code is: C(=O)(*)(*)>>CS(=O)C. 
 
  
                                         
 
Figure 15. Carbonyl replacement with a 2-isopropylidene-1,3-propanediamine 
group. The SMIRKS code is: C(*)(*)=O>>CC(=C(CN)CN)C. 
 
 
                                          
 
Figure 16. Carbonyl functional group replacement with a methylsulfonylmethane 
group. The SMIRKS code transformation: C(*)(*)=O>>CS(=O)(=O)C. 
 
 
                                              
 
Figure 17. Carbonyl functional group replacement with a N,N-dimethylacetamide) 
aka “DMAc” group. The SMIRKS code transformation: C(=O)(*)(*)>>CC(=O)N(C)C. 
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Figure 18. Carbonyl functional group replacement with an isobutylamine group. 
The SMIRKS code transformation: C(*)(*)=O>>CC(C)CN. 
 
                                     
                                                             
 
Figure 19. Carbonyl functional group replacement with a N-hydroxy-2-propanimine 
group. The SMIRKS code transformation: C(*)(*)=O>>CC(C)=NO. 
 
 
                                            
 
Figure 20. Carbonyl functional group replacement with a propan-2-one-O-methyl-
oxime. The SMIRKS code transformation: C(*)(*)=O>>CON=C(C)C. 
 
 
After several semesters of working on these fundamental transformations (some 
of which are listed above) the goal was to incorporate more advanced transformations 
using the latest cutting-edge transformations and/or structural modifications reported.  
The in silico transformations can be accomplished readily once the research has been 
published.  The reason this strategy was adopted is at least twofold:  (1) Transformations 
outlined in the Silverman text are essential to a rule-based transformation database 
because they are fundamental.  (2) The development of these rules, typically while quite 
simple, provided the necessary background to learn the SMILES and SMIRKS language. 
Below is a summary of research.  
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The best method for developing new transformations is targeting recent 
substitutions and transformations that have been published in the leading chemistry and 
medicinal chemistry journals. Thus, an aggressive approach identifying useful 
transformations and writing them in a generalized way with SMILES and SMIRKS codes 
was the most logical plan of attack. To demonstrate our approach, an example of a recent 
transformation published in Tetrahedron Letters is shown.  
 Dr. Marc J. Adler and Dr. Steven W. Baldwin have been involved in acid-base 
protecting group research at Yale University and Duke University.10 In 2009, in an effort 
to synthesize compounds involving 2,2-dimethylchromenes, a series of phenol based 
compounds was studied. The study showed a number of structural modifications in which 
2,2-dimethylchromenes could be substituted for phenols. Considering the quantity of 
compounds that incorporate phenol rings, having a substitution which could change 
biological activity without radically altering the structure of the compound could be 
extremely valuable. The phenol ring (shown on the left of the Figure 21 below) was 
converted to the 2,2-dimethylchromene structure (shown on the right). 
The transformation represents a potentially significant achievement. Having a 
transformation such as this within the Drug Guru and Bowen Research Group databases 
could be extremely helpful in a variety of areas. There is a simple SMILES and SMIRKS 
code that can be derived from this work. In order to maintain the integrity of the 
transformation, the benzene ring must be included in the code. On the product side, the 
new molecule has a ring formation that is attached to the benzene ring with an oxygen 
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atom enclosed and two additional carbons affixed. A SMILES code for this 
transformation would be c1c(O)cccc1>>CC1(C)Oc2ccccc2C=C1, while the SMIRKS 
code would be c1c(O)cccc1>>c1c(OC(C)(C)C=C2)c2ccc1. The two arrows (>>) 
represent the transformation, and they separate the left side and the right side of the 
equations. The lower case c's represent aromatic ring system carbon atoms. The (O) 
represents an oxygen atom that is attached to a carbon within that system. Note that the O 
that resides within the parentheses on the left hand side is also on the right hand side. 
However, the oxygen has now become part of a second, non-aromatic ring system. Those 
carbons are represented by upper case c(C). The two carbons that protrude from that 
second ring are represented by the (C)(C). When there is a double bond, it is represented 
by an equals sign (=). Inside the second ring structure, there is one double bonded pair of 
carbons. A triple bond would be represented by a ‘#’, but none are shown in this 
particular transformation example. When there is nothing in between two letters, a single 
bond is assumed. Ring structures have a beginning point and an ending point. These are 
represented by the numbers (1,2). Therefore, in the SMILES shown, the first c has a 1 
after it representing that this is the start of the aromatic ring, and after the sixth c, there is 
an additional 1, showing that this carbon is attached to the first carbon in the chain, 
thereby closing the ring. When this total transformation is viewed visually, it is easier to 
understand.   
As shown below, the transformation can be seen in its entirety. The implications 
of this type of research can be significant. Is it possible that this substitution would work 
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in other reactions? By including this transformation in our databases, there is an option to 
exploit this information. The transformation is shown in Figure 21 below, with the 
substituted area in blocks. 
 
         
                              
Figure 21. Compound 2-(1-hydroxy-3-methylbut-2-en-1-yl)phenol transformation to 
2,2-dimethylchromene. The SMIRKS code transformation: 
c1c(O)c(C(O)C=C(C)C)ccc1>>c1c(OC(C)(C)C=C2)c2cc(O)c1. 
 
   
Another example is taken from Dr. Christina Juli and her colleagues. They have 
been researching inhibitors to the Legionella MIP protein.11This protein is the primary 
cause for Legionnaire’s Disease and Pontiac fever. It affects people with impaired 
respiratory systems. A number of substitutions were carried out with favorable changes in 
MIP activity. In the compounds shown in the fourth substitution, there is a N(OH)2 group 
that is attached to a benzene ring coming off of a sulfur atom. The researchers substituted 
an amine in this location (as shown below in Figure 22).  A number of promising MIP 
inhibitors were found (using this substitution and a few others), and the transformations 
that were performed could turn out to be useful in other studies. 
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Figure 22. N,N-dihydroxyanaline to aniline. The SMIRKS code for this 
transformation: c1ccc(N(O)O)cc1>>c1ccc(N)cc1. 
 
 
The conversion to aniline is similar to the SMILES/SMIRKS example shown 
previously. The benzene ring is signified by lower case c’s representing an aromatic 
compound. Inside the parentheses are the attached groups. In the first side of the 
SMIRKS, the two oxygen atoms are represented. One is inside parentheses, and the other 
follows. This signifies that both oxygen atoms are attached to the nitrogen, but not to 
each other. On the right side of the equation, only the nitrogen is shown. This is because 
hydrogen atoms generally are not represented in the SMILES and SMIRKS codes as they 
are assumed to be there, much like chemistry line drawings.
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          CHAPTER VI 
 
   RESEARCH FIGURES AND DATA 
 
 
The following reactions are grouped based upon the substituted compound. In 
some cases, the compound noted would fit in more than one category. All figures shown 
are SMILES based. 
Benzanilide–Biphenyl Replacement: A Bioisosteric Approach to Quinoline 
Carboxamide-Type ABCG2 Modulators.12 
UR-COP78 has been shown to be a potent ABCG2 modulator. Through 
replacement of the labile benzanilide with a biphenyl group, improved stability was 
achieved, while still maintaining potency and selectivity. The transformation keeps both 
aromatic rings intact (see Figure 23), but removes the nitrogen and oxygen atoms from 
the connecting chain, making the new molecule slightly smaller.
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Figure 23. Benzanilide to biphenyl transformation (with parent structure and 
substituted area shown).The SMILES code 
transformation: O=C(Nc1ccccc1)c2ccccc2>>c1ccc(cc1)c2ccccc2. 
 
 
SMIRKS: 
[c:1]1[c:2][c:3][c:4]([c:5][c:6]1)C(=O)N[c:7]2[c:8][c:9][c:10][c:11][c:12]2>>[c:1]1[c:2][
c:3][c:4]([c:5][c:6]1)[c:7]2[c:8][c:9][c:10][c:11][c:12]2 
     
The bioisosteric similarity of the tetrazole and carboxylate anions: Clues from the 
topologies of the electrostatic potential and of the electron density.13 
Researchers examined the tetrazole and carboxylate anions to compare how well 
one could replace the other as a bioisosteric substitution. They found that they were 
remarkably similar in their electrostatic potentials, despite the fact that they exhibit 
significant differences in molecular geometry and constitution.  Clearly, one similarity is 
the ionizable hydrogen on both the carboxylic acid and the tetrazole.  This type of
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bioisosteric replacement is quite common in medicinal chemistry and is the basis for 
essentially all of the angiotensin II receptor antagonists. 
            
Figure 24. Carboxylic acid to 5-methyl tetrazole. The SMILES code transformation: 
CC(O)O>>CC1=NNN=N1. 
 
 
 SMIRKS: 
[C:1][C:2](O)O>>[C:1][C:2]1=NNN=N1. 
 
 
Benzothiazepine CGP37157 and its isosteric 2'-methyl analogue provide 
neuroprotection and block cell calcium entry.14 
Benzothiazepine CGP37157 has recently been identified as a neuroprotector in 
mitochondrial cells. ITH12505 is an isosteric analogue of CGP37157, with a chlorine 
atom being replaced by a methyl group on the phenyl ring. Both the chlorine and methyl 
groups are hydrophilic.  ITH12505 showed increased neuroprotective abilities. With 
continued research, it could be developed as an antioxidant in L-type voltage-dependent 
Ca2+ channels, where CGP37157 is currently being investigated. In the figure below, a 
chlorine atom has been removed from an aromatic ring and a methyl group has been 
added.  Note that in the structure right structure below, the added methyl group is shown 
on the opposite side of the benzene ring, but this is the same position that the chlorine 
atom originally occupied if the benzene ring was rotated 180°.   
32 
 
 
 
Figure 25. Compound 7-Chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-
2(3H)-one to 7-chloro-1,5-dihydro-5-(2-methylphenyl)-4,1-benzothiazepin-2(3H)-
one. The SMILES code transformation: 
Clc1ccccc1C3SCC(=O)Nc2c3cc(Cl)cc2>>Clc3cc1c(NC(=O) CSC1c2ccccc2C)cc3. 
 
SMIRKS: 
Cl[c:1]1[c:2][c:3][c:4]cc1C3SCC(=O)Nc2c3cc(Cl)cc2>>Cl[c:1]3[c:2][c:3]1[c:4](NC(=O
)CSC1c2ccccc2C)cc3 
 
 
BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with 
Arg-296.15 
Beta-secretase 1 (BACE1) is an enzyme in humans that is known to be involved 
in the advancement of Alzheimers Disease. A hydroxyethylamine template was used with 
substitutions to develop a potential inhibitor of BACE1. The interactions take place on 
the non-prime side of the molecule with Arg-296. In the transformation, a smaller ring 
structure has been replaced by a larger aromatic ring and a sulfonamide. When the 
substitution shown below was instituted, it increased inhibition in BACE-1C50 by as much 
as thirty fold. 
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Figure 26. Diphenylamine BACE-1 inhibitor with substitution site indicated. 
 
                           
 
 
Figure 27. Compound N,N-diphenylmethanesulfonamide to 1-phenyl-2-
pyrrolidinone. The SMILES code transformation: 
CS(=O)(=O)N(c1ccccc1)c2ccccc2>>O=C2CCCN2c1ccccc1. 
 
 
SMIRKS:  
CS(=O)(=O)[N:1]([c:2]1[c:3][c:4][c:5][c:6][c:7]1)c2ccccc2>>O=C2CCC[N:1]2[c:2]1[c:
3][c:4][c:5][c:6][c:7]1 
 
      
Synthesis and antiproliferative evaluation of 5-oxo and 5-thio derivatives of 1,4-
diaryl tetrazoles.16 
L1210 is a leukemic cell, and SkBr3 is a cell line frequently associated with 
breast cancer. Researchers developed a series of compounds that utilized substitutions on 
an aromatic ring at the side of a 5-thio derivative. These compounds had early success in 
inhibition on both L1210 and SkBr3. Conceptually, the transformation of a tetrazole 
carbonyl moiety to a tetrazole thiocarbonyl moiety is shown in Figure 28. 
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Figure 28. Compound 1,2-dihydro-5H-tetrazol-5-one to 1,2-dihydro-5H-tetrazole-5-
thione transformation (with parent structure to the left). The SMILES code 
transformation: O=C1NN=NN1>>S=C1NN=NN1. 
 
 
SMIRKS: 
O=[C:1]1[N:2][N:3]=[N:4][N:5]1>>S=[C:1]1[N:2][N:3]=[N:4][N:5]1 
 
Synthesis and biological evaluation of indolyl chalcones as antitumor agents.17 
 
Indolyl alkaloids have recently been found to have significant effects on P388 
leukemia cell cytotoxicity. Researchers tested a group of substituted indolyl chalcones for 
their anticancer activity against cell lines containing epithelial A-549, pancreatic 
carcinoma PaCa-2, and androgen-independent human prostatic adenocarcinoma PC-3 
cancer cells. Two of the substitutions showed significant cytotoxicity against all three 
cells, but had especially strong results when working with the PaCa-2 cells. In the 
transformation, the ring structures remain constant, but the side chains attached have been 
changed. 
 
      
 
Figure 29. Parent structure with five membered ring structure substitution. 
The SMILES code transformation: CC1OC(*)=NC=1>>CC1OC(*)=NN=1 
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SMIRKS: 
  CC1OC(*)=NC=1>>CC1OC(*)=NN=1 
 
  
Design of a series of bicyclic HIV-1 integrase inhibitors. Part 2: Azoles: Effective 
metal chelators.18 
HIV integrase is a retrovirus enzyme that allows HIV to place its genetic material 
into the DNA of a cell. A series of isosteres was developed as promising HIV integrase 
inhibitors. The substitutions were based upon a ring structure with a sulfur-carbon 
exchange. In Figure 30 (shown below), the sulfone part of the [1,2,5]thiadiazolidine 1,1-
dioxide ring is being replaced with a carbonyl and the CH3 is being replaced with an 
isopropyl.  
 
Figure 30.  Parent structure with 2-Methyl-1,2,5-thiadiazolidine 1,1-dioxide to 1-
Isopropyl-2-imidazolidinone substitution. The SMILES code 
transformation: CN1CCNS1(=O)=O>>CC(C)N1CCNC1=O. 
 
 
SMIRKS: 
[C:1][N:2]1[C:3][C:4][N:5]S1(=O)=O>>CC(C)[N:5]1[C:4][C:3][N:2][C:1]1=O 
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Trichoderins, novel aminolipopeptides from a marine sponge-derived Trichoderma 
sp., are active against dormant mycobacteria.19  
Researchers isolated three aminolipopeptides from marine sponges in an effort to 
inhibit mycobacterial growth. The substitutions shown were determined to be the most 
potent in anti-mycobacterial activity. In Figure 31 (shown below), the transformation 
involves converting the unsaturated carbon-carbon double bond to the corresponding 
saturated system with the addition of a hydroxyl group bonded to the beta-carbon. 
Although the newly generated structure is the synthetic precursor of the enone structure 
and generally more unstable, there is precedent in having electronegative groups beta to 
carbonyl functional groups.   
 
 
 
Figure 31. Parent compound with substitution site indicated followed by 5-Hydroxy-
3-hexanone to (4E)-4-hexen-3-one transformation. The SMILES code     
transformation:C\C=C\C(=O)CC>>CCC(=O)CC(C)O 
 
 
SMIRKS: 
[C:1]\[C:2]=[C:3]\C(=O)CC>>[C:1][C:2][C:3](=O)CC(C)O 
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Synthesis, aerobic cytotoxicity, and radiosensitizing activity of novel 2,4-
dinitrophenylamine tethered 5-fluorouracil and hydroxyurea.20 
A series of substituted N-(2,4-dinitro-phenylamino) compounds was developed as 
HT-29 inhibitors. The hope for this is an increase in radiosensitizing abilities on cancer 
cell lines. The two compounds shown in Figure 32 were among a series of substituted 
compounds based on a 2,4-dinitrophenylamine scaffolding which increased cancer 
inhibition. The specific targets would be adenocarcinomas, which is a cancer of the 
epithelium. In this transformation, the methoxyurea was replaced with the fluorouracil-
based compound, and it showed similar behavior in radiosensitizing. The transformation 
itself is a substitution of a smaller chain for a six membered aromatic ring. 
 
Figure 32. Parent structure with 1-methoxyurea to 5-Fluoro-3-methyl-2,4(1H,3H)-
pyrimidinedione transformation. The SMILES code transformation: 
CONC(=O)N>>Cn1c(=O)[nH]cc(F)c1=O. 
 
SMIRKS: 
CONC(=O)N>>Cn1c(=O)[nH]cc(F)c1=O 
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Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: 
Optimization of the 4-substituted piperidine.21 
In an effort to treat migraines, a series of substituted piperidines was developed as 
CGRP receptor antagonists. When combined with a dihydroquinazolinone and placed 
into a benzodiazepine core, these structures produced a stable, potent analog. As shown 
in Figure 33 below, the two ring structures are detached in the second compound. 
 
Figure 33. Parent structure with1,3-Dihydro-2H-imidazo[4,5-b]pyridin-2-one to 4-
phenyl-1,3-dihydroimidazol-2-one substitution (with attachment points indicated). 
The SMILES code transformation: 
O=C1[NH]C2CCCNC2[NH]1>>O=C1[NH]CC([NH]1)C2CCCCC2 
 
SMIRKS: 
O=C1C2CCCNC2N1>>O=C1NC(=CN1)C2CCCCC2 
 
 
Synthesis, Activity, and Pharmacophore Development for Isatin-β-
thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells.22 
β-Thiosemicarbazones have been found to be effective in the inhibition of P-
glycoprotein. P-glycoprotein gives multi-drug resistance to cancer cells. The elimination 
of this protein should result in better anticancer treatment options. The modified 
compound shown below in Figure 34 has some promising inhibition results. The essential 
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transformations resulted in the removal of a carbonyl group and the opening of a ring. 
The benzene ring is part of the parent structure (the entire structures are shown in the 
figure). 
 
         
 
Figure 34. Methisazone ((2Z)-2-(1-methyl-2-oxo-1,2-dihydro-3H-indol-3-
ylidene)hydrazinecarbothioamide) to (2E)-2-(2-aminobenzylidene) 
hydrazinecarbothioamide. The SMILES code transformation: 
S=C(N)N/N=C2/c1ccccc1N(C2=O)C>>S=C(N)N/N=C/c1ccccc1N. 
 
 
SMIRKS: 
S=C(N)N/N=C2/[c:1]1[c:2][c:3][c:4][c:5][c:6]1N(C2=O)C>>S=C(N)N/N=C/[c:1]1[c:2][
c:3][c:4][c:5][c:6]1 
 
 
New Analgesics Synthetically Derived from the Paracetamol Metabolite N-(4-
Hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide.23 
N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide (AM404) is 
an inhibitor of endocannabinoid cellular uptake. By shortening the acyl chain, 
bioisosteric compounds were developed that had similar analgesic activities. The most 
significant transformation in this case was the removal of the hydroxyl group and the 
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addition of another heteroaromatic ring.  Presumably the indazole nitrogen can supply a 
pair of electrons similar to the hydroxyl group. 
 
 
Figure 35. Compound AM404 with N-(4-hydroxybenzyl)acetamide to N-(1H-
indazol-5-yl)acetamide substitution. The SMILES code transformation: 
O=C(NCc1ccc(O)cc1)C>>CC(=O)Nc1cc2cnnc2cc 
 
 
SMIRKS: 
O=[C:1]([C:2])NCc1ccc(O)cc1>>[C:1][C:2](=O)NC1=CC2C=NNC2C=C1 
 
 
Effect of Thioxopeptide Bonds on α-Helix Structure and Stability.24 
Researchers have studied the effect of thioxoamides on protein structure and 
function. The thioxoamide bonds are similar in structure to amide bonds, but have 
different photophysical and hydrogen-bonding properties. Experimental results found that 
the substitution is tolerated, but there is some destabilization with the substitution. Given 
that the replacement of a carbonyl oxygen with a sulfur is an isosteric replacement, there 
are a number of situations in which a C=O could be substituted with a C=S. 
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Figure 36. N-Methylacetamide to N-Methylethanethioamide substitution with 
attachment points to an α-Helix (not shown) structure as indicated. The SMILES 
code transformation: O=C(NC)C>>S=C(NC)C 
 
 
SMIRKS: 
O=[C:1]([N:2][C:3])[C:4]>>S=[C:1]([N:2][C:3])[C:4] 
 
 
Cyclic amide bioisosterism: Strategic application to the design and synthesis of HCV 
NS5B polymerase inhibitors.25 
HCV NS5B polymerase has been identified as being an important factor in the 
Hepatitis C virus. In an effort to create successful thiophene carboxylate inhibitors of 
HCV NS5B polymerase, bioisosteric modeling was employed to create compounds that 
were compatible with the original amide inhibitors. In Figure 37, a triazole was 
substituted for a non-aromatic compound.  
                                                                     
Figure 37. Parent compound with amide-based bioisosteres and attachment points 
shown. The SMILES code transformation: CC(C)NC(*)=O>>*n1ccnn1. 
 
 
                                                    SMIRKS:  
                                      CC(C)NC(*)=O>>*n1ccnn1 
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Synthesis and biological evaluation of indolyl glyoxylamides as a new class of 
antileishmanial agents.26 
Leishmania is a disease that is transmitted by insect bites. Through the bite 
wound, a parasite is released into the host’s body. Eventually the parasite attacks vital 
organs. It has been proven to be very drug resistant. By synthesizing indolyl 
glyoxylamide derivatives, antileishmanial activity was increased. The substituted groups 
shown below (Figure 40) were attached at the bottom of a tricyclic ring structure as 
shown in Figure 39. The two molecules are very similar in size and shape, but the 
substitution of a bromine atom for an ethyl group gives it different properties. 
 
                             
 
Figure 38. Indole-3-glyoxylamide is shown. 
 
 
     
Figure 39. Connection point for the substituted ethylbenzen
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Figure 40. Ethylbenzene to bromobenzene transformation 
The SMILES code transformation: CCc1ccccc1>>Brc1ccccc1 . 
 
SMIRKS: 
c1(CC)ccccc1>>Brc1ccccc1 
 
1,2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 
(CARM1).27 
N(1)-benzyl-N(1)-methylethane-1,2-diamine was used as a substitute for (S)-
alanine benzylamide in the design of a CARM1 inhibitor. The simple substitution shown 
below attached to the diamine as listed, increased potency by greater than a factor of 
three with improved half-lives. 
                                           
Figure 41. N(1)-benzyl-N(1)-methylethane-1,2-diamine on the left with the 
substitution location boxed. N-methylethane-1,2-diamine to 2,2-diaminoacetamide 
substitution shown with attachment points in arrows. The SMILES code transformation: 
CNCCN>>NC(N)C(N)=O.  
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    SMIRKS: 
NCCNC>>NC(N)C(N)=O 
 
 
Heterocyclic acetamide and benzamide derivatives as potent and selective β3 
-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.28 
In an effort to treat symptoms involved in an overactive bladder, a series of 
adrenergic receptor agonists was investigated.  By isosteric substitution, selectivity within 
these agonists was significantly improved. In Figure 42, a number of substitutions have 
been made (including the introduction of a sulfur atom), but the size and shape of the 
molecules are very similar. 
                                       
           
Figure 42. Parent structure with 1-(propan-2-yl)-1H-pyrazole to 2,5-
dimethyl-4-ethylthiazole substitutions shown. The SMILES code transformation: 
CC(C)n1cccn1>>CCc1nc(C)sc1C. 
 
 
SMIRKS: 
CC(C)n1cccn1>>Cc1sc(C)nc1CC 
 
 
Thiopyrophosphoantigens: Solid-phase Synthesis and in Vitro Characterization of a 
New Class of Vγ9 Vδ2 T Cells Activators.29 
In the process of developing new phosphoantigens, a number of bioisosteric 
compounds were considered. In the process, 1-bromo-2-methyl-2-butanol and 2-methyl-
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but-2-ene were used. There is also consideration of a thiol group added or substituted in 
these compounds that could add to improved T-cell activation. 
   
                          
Figure 43. A prototype phosphoantigen with the substitution site shown. The 
substitution is 2-methyl-but-2-ene to 1-bromo-2-methyl-2-butanol. The SMILES code 
transformation: OCC(=C/C)/C>>BrCC(O)(C)CC 
 
 
   SMIRKS: 
                  O[C:1][C:2](=[C:3][C:4])[C:5]>> Br[C:1][C:2](O)([C:3])[C:4][C:5] 
 
 
Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen 
Receptor β.30 
A group of estrogen receptor ligands was synthesized by creating diaryl-
substituted salicylaldoximes and anthranylaldoximes. Replacement of the α-napthol ring 
with a hydrogen-bonded pseudocyclic ring, combined with the addition of a chlorine and 
oxygen, led to strong affinity and selectivity for estrogen receptor β over estrogen 
receptor α. 
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Figure 44. 6-(4-hydroxyphenyl)-2-naphthol to 2-chloro-4-[(E)-
(hydroxyimino)methyl]-3,4'-biphenyldiol. The SMILES code transformation: 
Oc3ccc(c1ccc2c(c1)ccc(O)c2)cc3>>c1cc(ccc1c2ccc(c(c2Cl)O)/C=N/O)O 
 
 
SMIRKS: 
O[c:1]3[c:2]cc(c1ccc2c(c1)ccc(O)c2)cc3>>[c:1]1[c:2]c(ccc1c2ccc(c(c2Cl)O)/C=N/O)O 
 
 
Analysis of the Reaction of Carbachol with Acetylcholinesterase Using Thioflavin T 
as a Coupled Fluorescence Reporter.31 
This research focused on the reaction of carbachol (carbamoylcholine) and 
acetylcholinesterase (AChE), which hydrolyzes the neurotransmitter acetylcholine. In 
determining distinctive electronic differences between affinities of compounds, carbachol 
was compared with acetylcholine and acetylthiocholine as an isosteric analogue.  
Replacement of a methyl group with an amine is an isosteric replacement.  In this case, 
the ester functional group becomes a carbamate, which adds stability to the molecule by 
reducing its propensity for hydrolysis. 
 
                                      
Figure 45. Acetylcholine to carbachol. The SMILES code transformation: 
CC(=O)OCC[N+](C)(C)C>>O=C(OCC[N+](C)(C)C)N. 
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SMIRKS:                              
C[C:1](=O)OCC[N+](C)(C)C>>O=C(OC[C:1][N+](C)(C)C)N 
 
 
Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: Control of 
selectivity by a benzyloxy group.32 
In the process of cancer screening, a number of Anaplastic Lymphoma Kinase 
(ALK) inhibitors were studied.  Transmembrane receptor tyrosine kinase has been found 
to be active in several different cancers. ALK was compared to VEGFR2-based kinase. A 
loss of entropy in the bound form of the VEGFR-2 kinase in comparison with the former 
could explain the activity reduction. The addition of two dihydro-fluoro-difluoro groups 
also could play a significant role in this change in activity. 
 
 
        
Figure 46.  ALK inhibitor with substitution site shown, followed by benzyl alcohol to 
(2,3-difluorophenyl)methanol substitution. The hydrogen atoms are not shown in the 
figures, since the oxygens would not be protonated when connected to the main structure. 
The SMILES code transformation: c1ccccc(CO)1>>c1ccc(F)c(F)c(CO)1. 
 
SMIRKS: 
[c:1]1[c:2]=[c:3][c:4]=[c:5][c:6]([C:7][O:8])1>>[c:1]1[c:2]=[c:3](F)[c:4]=[c:5](F)[c:6]([
C:7][O:8])1 
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Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone 
derivatives as inhibitors of cathepsin L.33 
Cathepsin L is a protein that has been identified in a number of myofibral and 
myocardial processes. The isomeric substitutions shown below were present in active 
inhibitors of Cathepsin L without affecting Cathepsin B (a protein that has actually been 
identified as helpful in the battle against Alzheimers Disease).  It is not unreasonable to 
assume that a 1,2-bromo shift would lead to other activity in other circumstances given  
the flexible nature of receptors. 
 
 
                                                              
Figure 47. Benzophenone thiosemicarbazone cathepsin L inhibitor showing 
substitution site. 
 
 
                    
        Figure 48. 3-bromophenol to 2-bromophenol substitution. 
              The SMILES code transformation: Oc1cc(Br)ccc1>>Oc1c(Br)cccc1 
 
 
SMIRKS:  
       O[c:1]1[c:2][c:3](Br)[c:4][c:5][c:6]1>> O[c:1]1[c:2](Br)[c:3][c:4][c:5][c:6]1  
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DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological 
activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-
one chemotype.34 
Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-one (NU7441) was 
previously developed as a DNA-dependent protein kinase inhibitor. Using a variety of 
substitutions (shown below) on a scaffolding, the inhibition effects were observed in a 
number of the compounds. In the case of the two substituents (from Figure 50), they 
would be replacing the morpholine structure on the far right of Figure 49. An additional 
rule substitution using that molecule could be forthcoming in future coding.  
                                 
Figure 49. NU 7441, an antitumor agent and DNA-Protein Kinase inhibitor with site 
of substitution indicated. 
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Figure 50. Compound pyrimidin-4(3H)-one with 2,3-dihydropyridin-4(1H)-one (1:1) 
substitution. The SMILES code transformation:  O=C1C=CN=CN1>>O=C1C=CNCC1. 
 
SMIRKS: 
     O=C1C=CN=CN1>>O=C1C=CNCC1 
 
       
Exploring alternative Zn-binding groups in the design of HDAC inhibitors: Squaric 
acid, N-hydroxyurea, and oxazoline analogues of SAHA.35 
Histone deacetylase inhibitors are used in a number of neurological and 
psychiatric drugs. A series of suberoylanilide hydroxamic acid (SAHA) substituted 
compounds was synthesized and evaluated for their inhibitory and cytotoxic activity. The 
compounds shown in Figure 52 would be substituted for the far right end of the molecule 
in Figure 51. Essentially, a five membered ring structure is replacing the hydroxyurea 
portion. 
 
                                              
 
Figure 51. Substituted Suberoylanilide Hydroxamic Acid (SAHA) compound with 
transformation area highlighted. 
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Figure 52. 1-Hydroxy-3- methylurea to (2-methyl-4,5-dihydro-1,3-oxazol-4-
yl)methanol substitution. The SMILES code transformation: 
CC1=NC(CO)CO1>>CNC(=O)NO 
 
 
                                   SMIRKS:  
                                    CC1=NC(CO)CO1>>ON(=O)NC 
 
Design and evaluation of new antipsoriatic antedrug candidates having 16-en-22-
oxa-vitamin D3 structures.36 
In an effort to treat psoriasis with minimal side effects, a group of substituted 
antidrugs were created. They increased antiproliferation activity, while lessening 
calcemic activity (in comparison to currently prescribed drugs). In these trials, a number 
of different compounds were attached to the lone carbon at the top of the scaffolding 
shown in Figure 53. The two figures shown in Figure 54 were among the most promising. 
The second compound in Figure 54 is similar in size and shape, but has significant 
differences in electronegativity due to the addition of five fluorine atoms. 
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Figure 53. 16-en-22-oxa-vitamin D3 scaffolding with substitution site. The substituted 
molecules replace the hydrogen atom shown in the hydroxide in the box. The TBSO on 
top of the six membered ring to the left of the figure is attached at the top of that ring, and 
not at the connection point between the two rings. 
 
                                         
Figure 54. Propan-2-ol to N-(2,2,3,3,3-pentafluoropropyl)acetamide substitution. 
These were two substitutions (in addition to the replaced group shown in Figure 53). The 
SMILES code transformation:CC(O)C>>FC(F)(F)C(F)(F)CNC(=O)C 
 
 
SMIRKS: 
CC(O)(CC)CC>> FC(F)(F)C(F)(F)CNC(=O)C 
 
 
Mechanistic Studies of Choline Oxidase with Betaine Aldehyde and Its Isosteric 
Analogue 3,3-Dimethylbutyraldehyde37  
Studies involving choline inhibition have compared betaine aldehyde and 3,3-
dimethylbutanal. The two compounds resemble each other sterically at the quaternary 
centers, with only the substitution in the center of the molecule being the difference 
between the two. Despite the geometric similarities, the 3,3-dimethylbutanal displayed 
significantly reduced flavin reduction in experiments performed by the researchers. 
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Figure 55. Betaine aldehyde to 3,3-dimethylbutyraldehyde substitution. The SMILES 
code transformation: O=CC[N+](C)(C)C>>O=CCC(C)(C)C. 
 
 
    SMIRKS: 
     [O:1]=[C:2][C:3][N+]([C:4])([C:5])([C:6])>>[O:1]=[C:2][C:3]C([C:4])([C:5])([C:6]) 
 
 
Reactions of Oxetan-3-tert-butylsulfinimine for the Preparation of Substituted 3-
Aminooxetanes.38 
An oxetane ring has been used in a number of bioisosteric substitutions involving 
dimethyl and carbonyl groups. In this study, 3-aminooxetanes were developed through 
reactions involving oxetan-3-tert-butylsulfinimine and the corresponding 
sulfinylaziridine. In the preparation of these molecules, the compounds in Figure 56 were 
attached to sulfinimines to create 3-aminooxetanes that could serve as bioisosteric 
replacements for geminal dimethyl groups. The larger phenyl group was substituted in 
this case, and may have limited use, but the transformation was noted. 
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Figure 56. Parent structure with 2-propanamine to 3-oxetanamine with 
attachment points. The SMILES code transformation: CC(N)(C)>>NC1COC1. 
 
 
SMIRKS:  
CC([N:1])(C)[c:2]1ccccc1>>[N:1][C:2]1COC1 
 
 
Synthesis of a 6-Methyl-7-deaza Analogue of Adenosine that Potently Inhibits 
Replication of Polio and Dengue Viruses.39 
Tubercidin is a natural glycolysis inhibitor. Mimics of adenosine and adenosine 
triphosphate (ATP) have been found to be effective in therapeutics. Synthesis of a 
tubercidin analogue was found to be an acceptable substitution for adenosine in a number 
of categories. 6-Methyl-9-β-D-ribofuranosylpurine was eventually isolated and also found 
to be an effective substitution. The substitution of a carbon atom for a nitrogen atom in 
the aromatic ring was the only change. 
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Figure 57. Adenosine to tubercidin (7-(β-D-Lyxofuranosyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine). The SMILES code 
transformation:   
c1nc(c2c(n1)N(cn2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)C 
>>Cc3ncnc2c3ccn2[C@@H]1O[C@H](CO)C(O)C1O 
 
 
SMIRKS: 
c1nc(c2c(n1)n(cn2)[CH]3[C]([C]([C](O3)CO)O)O)N>>Nc3ncnc2c3ccn2[C]1O[C](CO)
C(O)C1O 
 
 
The Steric Hypothesis for DNA Replication and Fluorine Hydrogen Bonding 
Revisited in Light of Structural Data.40 
Researchers studying DNA replication have hypothesized that molecular 
geometry is more important than hydrogen bonding in certain situations. Using 2,4–
difluorotoluene as a bioisosteric substitute for thymine seemed to verify the idea because 
fluorine was thought to be a poor hydrogen bond acceptor. In this study, however, it was 
determined that both the geometry and hydrogen bonding are equally important in the 
substitutions, and the fluoro group is capable of engaging in hydrogen bonding in many 
cases.  
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Figure 58. Thymine to 2,4 – difluorotoluene substitution. The SMILES code 
transformation: Cc1c[nH]c(=O)[nH]c1=O>>Fc1cc(F)c(cc1)C. 
 
 
SMIRKS: 
C[c:1]1c[nH]c(=O)[nH]c1=O>>Fc1cc(F)c(c[c:1]1)C 
 
 
Thermodynamic Insights on the Structure and Energetics of s-Triphenyltriazine.41 
When testing the two compounds shown below, researchers found that they are 
isosteres. The triazine, however, has a higher stability because of the geometry. The 
authors suggested that the geometry decreased the volatility, which could explain the 
increase in stability. This led to the conclusion that ring-ring torsion effects played a 
major portion in the decrease in stability for the latter. Aside from the change in 
geometry, there is also a significant substitution in the center ring, where three nitrogen 
atoms have been replaced with carbon atoms.  
 
Figure 59. 2,4,6-Triphenyl-1,3,5-triazine to 1,3,5-triphenylbenzene substitution. 
The SMILES code transformation: 
n2nnc(c1ccccc1)c(c2c3ccccc3)c4ccccc4>>c1cc(ccc1)c2cc(cc(c2)c3ccccc3)c4ccccc4 
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SMIRKS: 
n2nnc([c:1]1[c:2][c:3][c:4][c:5][c:6]1)c(c2c3ccccc3)c4ccccc4>>[c:1]1[c:2][c:3]([c:4][c:5
][c:6]1)c2cc(cc(c2)c3ccccc3)c4ccccc4 
 
 
Synthesis of new 4-aminoquinolines and quinoline–acridine hybrids as antimalarial  
 
agents.42 
 
Chloroquine (CQ) is one of the two most widely used antimalarial drugs in the 
world. It is a relatively inexpensive drug and is readily available. Unfortunately, 
resistance has been steadily increasing towards CQ. Substitutions were made to 4-
aminoquinolines and quinolone-acridine (acridine shown in Figure 60 and chloroquine 
shown in Figure 61) hybrids. The substituted compounds were found to be equal to four 
times as powerful as CQ in dosage. The transformation in Figure 63 involves little in 
terms of changing elements, but involves a bringing together of two ring structures, 
which will have a difference in steric effects. 
  
           
 
Figure 60. Example of an acridine molecule. 
 
                                           
Figure 61. Chloroquine is used to treat malaria.
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                                 Figure 62. Molecule with site of substitution. 
 
 
                                
Figure 63. Compound 1,2,3,4-tetrahydroisoquinoline to 1-(2-pyridinyl)piperazine. 
The arrows indicate the points of attachment. The SMILES code transformation: 
C1Cc2ccccc2CN1>>c1nc(ccc1)N2CCNCC2. 
 
 
SMIRKS: 
[C:1]1Cc2ccccc2CN1>>[c:1]1nc(ccc1)N2CCNCC2 
 
 
4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake 
inhibitors: design, synthesis and structure-activity relationships.43 
Structure-activity relationships with piperidine and pyrrolidine derivatives as 
norepinephrine reuptake inhibitors (NRI’s) and serotonin norepinephrine reuptake 
inhibitors (SNRI’s) were investigated. It was found that dual ring substitution allowed for 
selection of NRI’s and SNRI’s. Additional pharmacological studies are ongoing. As can 
be seen in Figure 64 below, the nitrogen has changed positions with a carbon in the
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aromatic ring structure, and the six member piperidine ring has been replaced with a five 
member pyrrolidine ring. 
 
                    
Figure 64. Compound 3-(4-Piperidinylmethyl)pyridine to 4-(3-
pyrrolidinylmethyl)pyridine substitution.The SMILES code transformation: 
c1ncccc1CC2CCNCC2>>C(C1CCNC1)c2ccncc2. 
 
 
SMIRKS: 
c1[n:1][c:2][c:3]cc1CC2CCNCC2>>C(C1CCNC1)c2cc[n:1][c:2][c:3]2 
 
Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-
yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. 
Part 2.44 
Kv1.3 is a potassium voltage-gated channel that is important in a number of body 
regulations, including heart rate, secretion of insulin, muscle contraction, and 
neurotransmitter release. With such a variety of functions, the ability to regulate this 
channel is essential. Researchers are developing potential Kv1.3 channel blockers using 
N-3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propylbenzamide analogs. Kv1.3 
channel blockers using N-3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl-
benzamide analogs. The substitutions are shown are at the far right end of the molecule in  
Figure 65
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Figure 65. Site of substitution for 1-Cyclopropylmethanamine to 1,1,1-Trifluoro-2-
propanol. 
 
 
                                                
Figure 66. 1-Cyclopropylmethanamine to 1,1,1-Trifluoro-2-propanol with 
attachment points shown by arrows. The SMILES code transformation: 
NCC1CC1>>CC(O)C(F)(F)F. 
 
 
SMIRKS: 
NCC1CC1>>CC(O)C(F)(F)F 
 
 
Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery 
of potent and selective JAK2 inhibitors.45 
The human protein, janus kinase 2 (commonly known as JAK2) is believed to be 
involved in growth regulation. The lack of this protein has been shown to kill laboratory 
mice within 12 days. Regulation of this protein is very important. When working with a 
number of potential inhibitors, thiazol-2-yl amine was selected as a potential isosteric 
replacement for pyrazol-3-yl amine. The structures are very similar, but the arrangements 
of the atoms on the ring structure (and the sulfur substitution for nitrogen) give the 
molecules different activities. 
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Figure 67. Parent structure with 1-methyl-1H-pyrazol-3-amine to 5-methyl-1,3-
thiazol-2-amine substitution. The SMILES code transformation: 
Nc1ccn(C)n1>>Cc1cnc(N)s1. 
 
 
SMIRKS:  
[N:1][c:2]1ccn(C)n1>> Cc1cn[c:2]([N:1])s 
 
        
Structural Insights into the Dual Activities of the Nerve Agent Degrading 
Organophosphate Anhydrolase/Prolidase.46 
The bimetalloenzyme organophosphate acid anhydrolase (OPAA) is known to 
inhibit a number of acetylcholinesterase-inhibiting organophosphorus compounds, 
including toxic nerve agents. In an effort to obtain a better understanding of how this 
compound works, glycolate tendencies were observed and noted. The glycolate 
compounds appear to be very active and may explain some of OPAA’s tendencies. The 
substitution is minor (the hydroxyl group replaces the amine to the far left of the 
molecule) yet it seems to affect the activity considerably. 
 
 
62 
 
 
 
 
Figure 68. Glycine to glycolic acid transformation. The SMILES code transformation: 
C(C(=O)O)N>>C(C(=O)O)O. 
                                                  
 
     SMIRKS:  
[C:1]([C:2](=[O:3])[O:4])N>>[C:1]([C:2](=[O:3])[[O:4]])O 
 
 
Novel substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-
diones and 5-((N-benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-
triones as potent radio-sensitizing agents.47 
HT-29 is an aggressive adenocarcinoma found in colorectal cancers. A series of 
derivatives was analyzed for their ability to reduce activity of the HT-29 cell line. The 
substituted portions of these derivatives were the cyclic compounds shown below. The 
substitutions for the groups include a larger ring structure in the compound to the right 
(see Figure 69) and an additional oxygen atom double bonded to the ring. 
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Figure 69. Parent compound with substitution area (boxed) with imidazolidine-2,4-
dione to pyrimidine-2,4,6(1H,3H,5H)-trione transformation, with attachment points 
indicated by arrows. The SMILES code formatting: 
O=C1NC(=O)CN1>>O=C1CC(=O)NC(=O)N1. 
 
 
SMIRKS: 
O=C1NC(=O)CN1>> O=C1CC(=O)NC(=O)N1 
 
Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain48 
Researchers used a variety of substituted pyrazolopyridazine alpha-2-delta-1 
ligands in an effort to control neuropathic pain. In the case of the substitution shown in 
Figure 70, a chlorine atom is substituted with a fluorine atom on the left side of the 
aromatic ring. The trifluoromethyl group on the right of the structure has been replaced 
with a two carbon chain. While the size of these molecules are very similar, their 
activities are quite different. 
  
64 
 
 
              
Figure 70. Parent structure with 3-chlorophenyl trifluoromethyl ether to 1-ethoxy-3-
fluorobenzene substitution. The SMILES code transformation: 
Clc1cc(OC(F)(F)F)ccc1>>CCOc1cccc(F)c1. 
 
 
                                                SMIRKS:  
                   Clc1cc(OC(F)(F)F)ccc1>> CCOc1cccc(F)c1 
 
 
Recognition Properties of Carboxylic Acid Bioisosteres: Anion Binding by 
Tetrazoles, Aryl Sulfonamides, and Acyl Sulfonamides on a Calix[4]arene 
Scaffold.49 
Tetrazoles, aryl sulfonamides, and acyl sulfonamides are often used as 
substitutions for carboxylic acids in drug development. These compounds often show 
improved stability and potency. Presumably, the acyl group when bonded to the 
sulfonamides makes the N-H group more acidic (i.e., decreases the pKa), which enhances 
the solubility and mimics a carboxylate group. The substitution in Figure 71 is coming 
off of the aromatic ring, where a tetrazole is being replaced by an acyl sulfonamide. 
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Figure 71. 5-phenyl-1H-tetrazole with substituted compounds. The hydrogen attached 
to the sulfur has been removed, since it will not be present when attached to the parent 
structure. The SMILES code transformation: n1nnnc1>>O=S(=O)(NC(=O)C) 
 
 
SMIRKS: 
n1nnnc1>>O=S(=O)(NC(=O)C)1 
 
 
2-Aryl-4,5,6,7-tetrahydro-1,3-benzothiazol-7-ols as a class of antitumor agents 
selectively active in securin−/− cells.50 
A group of 2-(4-aminophenyl)-4,5,6,7-tetrahydro-1,3-benzothiazol-7-ol 
derivatives was investigated as potential antitumor agents. A substitution was made in the 
six membered ring with the replacement of a carbon atom with a nitrogen atom. That 
substitution seemed to have a definite impact on the antitumor abilities. 
 
 
Figure 72. Parent structure with 4,5,6,7-tetrahydro-1,3-benzothiazol-7-ol to 4,5,6,7-
tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol substitution. The SMILES code 
transformation: OC1CCCc2ncsc12>>OC1CNCc2ncsc12. 
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SMIRKS: 
O[C:1]1[C:2]C[C:3][c:4]2[n:5][c:6][s:7][c:8]12>>O[C:1]1[C:2]N[C:3][c:4]2[n:5][c:6][s:
7][c:8]12 
 
 
Design and synthesis of cell potent BACE-1 inhibitors: structure-activity 
relationship of P1' substituents.51 
A number of hydroxyethylamine BACE-1 inhibitors were manipulated to increase 
cathepsin-D inhibition. The compounds examined were six membered rings with a 
variety of attachments and compounds. The most effective substitution is shown in the 
figure below.  
 
 
Figure 73. Parent structure with 4,5,6,7-Tetrahydro-1H-indazole to 5,6,7,8-
Tetrahydro-2-quinazolinamine substitution. The SMILES code 
transformation: C1CCc2[nH]ncc2C1>>Nc1nc2CCCCc2cn1 
 
 
SMIRKS: 
[C:1]1CCc2[nH]ncc2C1>>Nc1nc2[C:1]CCCc2cn1 
 
 
Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do 
not show significant stereoselectivity.52 
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A group of imidazolylpropylguanidines and 2-aminothiazolylpropylguanidines 
were substituted and synthesized in an effort to produce potent histamine H2 receptor 
(H2R) agonists. The substituted compound had a similar size to the original compound 
(with only a sulfur atom replacing a nitrogen atom), but there are also a nitrogen and 
carbon atom attached to the aromatic ring that may have increased the agonist’s potency. 
       
                                
 
Figure 74. Parent structure with 1H-imidazole to aminomethiazole substitution. The 
SMILES code transformation: c1cn(C)cn1>>Cc1csc(N)n1. 
 
 
SMIRKS:  
      [c:1]1[c:2][n:3](C)cn1>>C[c:1]1[c:2]sc(N)[n:3]1 
 
 
1,2,3-Triazole–Heme Interactions in Cytochrome P450: Functionally Competent 
Triazole–Water–Heme Complexes.53 
1,2,4-Triazole is a recognized Cytochrome P450 inhibitor. For whatever reason, 
1,2,3-triazole has not received the same status. A number of pharmaceuticals utilize 
1,2,4-triazole for heme-nitrogen interactions, but none use the 1,2,3-triazole. When 
substituted onto a scaffold, it was found that the ligand positioning was altered. The 
1,2,3-triazole did not exhibit the same inhibitory effects, but it did offer a unique 
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regioselectivity that could allow it to be used in other situations. The transformation here 
is simply a rearrangement of nitrogen and carbon placement on the triazole’s ring 
structure. 
 
             
 
Figure 75. 1,2,3-triazole to triazole substitution. The SMILES code 
transformation: N1=NNC=C1>>ON1=NNC(*)=C1. 
 
 
SMIRKS:  
n1[c:1][c:2][n:3][n:4]1>> c1[c:1][n:2][n:3][nH]1 
 
          
Design and Synthesis of Celecoxib and Rofecoxib Analogues as Selective 
Cyclooxygenase-2 (COX-2) Inhibitors:  Replacement of Sulfonamide and 
Methylsulfonyl Pharmacophores by an Azido Bioisostere.54 
In an effort to design selective cyclooxygenase-2 (COX-2) Inhibitors, researchers 
modified celecoxib and rofecoxib analogues by using the bioisosteric substitution shown 
below. The substitution increased anti-inflammatory and analgesic activities in the 
analogues tested. The substituted compound had a similar five-member cyclic ring 
system, but had a number of atom changes (including the removal of all fluorine and 
nitrogen atoms, some of which were replaced by oxygen atoms). 
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Figure 76. Parent structure with 5-(trifluoromethyl)-1H-pyrazole to 2(5H)-furanone 
substitution. The SMILES code 
transformation: c1c[nH]nc1C(F)(F)F>>O=C\1OC/C=C/1. 
 
 
                                                              SMIRKS:  
                            [c:1]1c[nH]nc1C(F)(F)F>>O=[C:1]\1OC/C=C/1  
 
      
Exploring Aromatic Chemical Space with NEAT: Novel and Electronically 
Equivalent Aromatic Template.55 
Computer modeling simulations were used to develop biosisosteres. Properties 
such as electrostatic potential charges, reactivity, hydrogen bonding ability, and dipole 
moments were explored when calculating potential substituent ring structures. The 
transformation of 2-methyl-1-benzofuran to 2-methyl-1,3a-dihydropyrazolo[1,5-
a]pyridine was found to fit these qualifications. The ring structures are very similar in 
size, but have different abilities based upon the substitution of nitrogen atoms for the 
oxygen and carbon atoms in the original structure and the change in bonding. The areas 
circled indicate the points of attachment. 
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Figure 77. Parent structure with 2-methyl-1-benzofuran to 2-methyl-1,3a-
dihydropyrazolo[1,5-a]pyridine substitution. The SMILES code transformation: 
Cc1cc2ccccc2o1>>CC1=CC2C=CC=CN2N1. 
 
 
                                                SMIRKS:  
[C:1][c:2]1[c:3]c2ccccc2o1>>[C:1][C:2]1=[C:3]C2C=CC=CN2N1 
 
 
Identification of target family directed bioisosteric replacements.56 
 
Forty protein families were analyzed as potential bioisosteres. These bioisosteres 
were isolated and found to target a dozen different groups including nuclear hormone 
receptors and tyrosine kinases. In this transformation, the sulfur atom was replaced by a 
carbon atom, and the five-member ring was expanded to a six member ring. 
      
Figure 78. 2-R-Thiophene to 3-R-1,4-cyclohexadiene substitution. The 
SMILES code transformation: s1cccc(*)1>>c1ccccc(*)1. 
 
SMIRKS: 
s1[c:1][c:2][c:3][c:4](*)1>>[c:1]1[c:2][c:3][c:4]cc(*)1 
 
 
            
71 
 
 
In vitro and in vivo antimalarial evaluation of semi-synthetic derivatives of 
gomphostenin.57 
Sathe and coworkers are actively studying gomphostenins (compounds that are 
derived from the gomphostemma plant) for their antimalarial properties. By making 
substitutions, two of these derivatives were found to actually have more success than 
gomphostenins themselves. The substitution was one substituent switch of a fluorine 
atom for a chlorine atom. This should not affect the overall size or shape of the molecule 
significantly, but the greater electronegativity of a fluoro group would alter the 
electrostatics. 
 
 
 
Figure 79. Parent structure with 1-Chloro-4-ethylbenzene to 1-Fluoro-4-
ethylbenzene substitution. The SMILES code transformation: 
CCc1ccc(Cl)cc1>>CCc1ccc(F)cc1. 
 
 
SMIRKS: 
[C:1][C:2][c:3]1[c:4][c:5][c:6](Cl)[c:7][c:8]1>>[C:1][C:2][c:3]1[c:4][c:5][c:6](F)[c:7][c:
8]1 
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Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.58 
Starting from the known FXR (farnesoid X receptor, a sensor in the bile that 
works with nuclear receptors in bile acid uptake, metabolism and excretion regulation) 
agonist GW 4064 1a, a series of alternately 3,5-substituted isoxazoles was prepared as 
FXR agonists. The substitutions involved the cyclocompounds shown below. With either 
substituted ring compound, the potency remained the same. For this transformation, the 
aromatic ring remains constant, but the attachments completely changed. The two 
chlorine atoms were replaced by two carbon atoms and a hydroxyl group.  
 
       
Figure 80. Parent compound GW 4064 with the substitution site indicated followed 
by the transformation of 1,3-dichlorobenzene to 2-methoxy-1,3-dimethylbenzene. 
The SMILES code transformation: Clc1cccc(Cl)c1>>Cc1c(OC)c(C)ccc1. 
 
SMIRKS:   
Cl[c:1]1[c:2][c:3][c:4][c:5](Cl)[c:6]1>>C[c:1]1[c:2](OC)[c:3](C)[c:4][c:5][c:6]1 
 
 
Tricyclic sulfones as orally active γ-secretase inhibitors: Synthesis and structure–
activity relationship studies.59 
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In a design study of γ-secretase inhibitors, a series of substituted tricyclic sulfones 
(including BMS-708163, as shown below) was developed and found to be very potent. 
This potency could be used in the future development of new pharmaceuticals for the 
treatment of Alzheimer’s disease. In the transformation, the chlorine atom was 
substituted for the trifluoromethyl group.  
 
Figure 81. BMS 708163 (with substitution site indicated) followed by 
transformation of 1-chloro-4-(methylsulfonyl)benzene to 1-(methylsulfonyl)-
4-(trifluoromethyl)benzene. The SMILES code transformation: 
O=S(C)(=O)c1ccc(Cl)cc1>>O=S(C)(=O)c1ccc(cc1)C(F)(F)F 
 
 
SMIRKS: 
[O:1]=[S:2]([C:3])(=[O:4])[c:5]1[c:6][c:7][c:8](Cl)([c:9][c:10]1) 
>>[O:1]=[S:2]([C:3])(=[O:4])[c:5]1[c:6][c:7][c:8]([c:9][c:10]1)C(F)(F)F 
 
 
Pyridylmethylthio derivatives as VEGF inhibitors. Part 160 
Vascular endothelial growth factor (VEGF) is important in vasculogenesis and 
angiogenesis. Normally, it is useful in creating new blood vessels. Unfortunately, when 
overexpressed, it can lead to a number of vascular diseases. It can also provide blood 
flow to cancers that would otherwise be unable to survive. In this study, a number of 
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pyridylmethylthio substituted compounds were developed and found to be very active in 
VEGF inhibition. In this case, the aromatic ring remains constant, but a 
trifluoromethyoxy group has replaced two carbon attachments. 
                            
Figure 82. Parent inhibitor with substitution site indicated (box) followed by m-
xylene to (trifluoromethoxy)benzene transformation. The SMILES code 
transformation: Cc1cccc(C)c1>>FC(F)(F)Oc1ccccc1. 
 
 
                                                            SMIRKS: 
C[c:1]1[c:2][c:3][c:4][c:5](C)[c:6]1>>FC(F)(F)O[c:1]1[c:2][c:3][c:4][c:5][c:6]1 
 
 
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring  
Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor.61 
While working with γ-secretase inhibitor (BMS-708163), researchers decided to 
substitute Bicyclo[1.1.1]pentane for the fluorobenzene that was currently in the 
compound. When the substitution was made, it led to a compound that had the same 
potency as before, but with increases in passive permeability and aqueous solubility. This 
shows that the bicycle ring has capapilities beyond just being a “spacer”. 
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Figure 83. BMS 708163 with substitution site indicated followed by a phenyl ring (in 
this case, fluorobenzene) to bicyclo[1.1.1]pentane. The arrows indicate attachment 
points. The SMILES code transformation: Fc1ccccc1>>C1C2CC1C2. 
 
 
SMIRKS:  
Fc1ccccc1>> C1C2CC1C2 
 
Novel thienopyrrole glycogen phosphorylase inhibitors: Synthesis, in vitro SAR and 
crystallographic studies.62 
In an effort to design a potent glycogen phosphorylase a (GPa) inhibitor, a 
number of thienopyrrole substituted compounds were synthesized. These substitutions led 
to reduced glucose output from rat hepatocytes. For the transformation, the aromatic six 
member ring structure remains constant, but the attached ring expands from a five 
member carbon ring to a six member ring with a nitrogen substituent and an attached 
oxygen. 
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Figure 84. Inhibitor with substitution point indicated followed by transformation of 
indane to 3,4-dihydro-2(1H)-quinolinone. The SMILES code 
transformation: c1cccc2CCCc12>>O=C1CCc2ccccc2N1. 
 
 
SMIRKS: 
[c:1]1[c:2][c:3][c:4][c:5]2CCC[c:6]12>>O=C1CC[c:1]2[c:2][c:3][c:4][c:5][c:6]2N1 
 
 
Discovery of novel 1-phenyl-cycloalkane carbamides as potent and selective influenza fusion 
inhibitors.63 
Hemagglutinin (HA) is a protein that binds to sialic acid receptors on cells and is 
active in the influenza virus. Researchers used substituted 1-phenyl-cycloalkane 
carbamides to develop a potent HA inhibitor. The transformation from the piperidine 
keeps the ring structure, but converts to an aromatic structure with the addition of two 
side chains. The circles in Figure 86 indicate the points of attachment. 
 
 
                                                           
 
Figure 85. Structure showing the piperidine molecule’s location before substitution. 
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Figure 86. Piperidine to 4-(aminomethyl)-N-methylaniline transformation. The 
SMILES code transformation: C1CCCCN1>>c1c(NC)ccc(CN)c1. 
 
SMIRKS: 
C1CCCCN1>> CNc1ccc(CN)cc1 
 
Ureas with histamine H3-antagonist receptor activity—A new scaffold discovered by 
lead-hopping from cinnamic acid amides.64 
Histamine H3 (hH3) receptors are active in the central and peripheral nervous 
systems as neurotransmitter modulators. Treatment of these receptors has opened up a 
wide range of potential drugs for pharmacologic intervention for a wide range of 
diseases, ranging from obesity to sleep apnea. In this study, a series of substituted urea 
compounds was utilized as hH3 antagonists. The substitution in this transformation is on 
the left side of the molecules. The carbon-carbon double bond is replaced by a carbon 
atom attached to a nitrogen atom. 
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Figure 87. Parent compound with substitution site (box) followed by 4-
vinylbenzotrifluoride to 1-[4-(trifluoromethyl)phenyl]methanamine transformation. 
The SMILES code transformation: FC(F)(F)c1ccc(C=C)cc1>>FC(F)(F)c1ccc(cc1)CN. 
 
 
SMIRKS: 
[F:1][C:2]([F:3])([F:4])[c:5]1[c:6][c:7][c:8](C=C)cc1>>      
[F:1][C:2]([F:3])([F:4])[c:5]1[c:6][c:7][c:8](cc1)CN 
 
 
Cyclopentane-1,3-dione: A Novel Isostere for the Carboxylic Acid Functional 
Group. Application to the Design of Potent Thromboxane (A2) Receptor 
Antagonists.65  
Because cyclopentane-1,3-dione has a pKa value similar to a carboxylic acid, 
researchers investigated the possibility of using it as a bioisostere. When comparing the 
properties of the compound to other carboxylic acid isosteres (such as tetrazole), it 
matched up favorably. A number of experiments were carried out to determine if 
cyclopentane-1,3-dione would be a suitable isostere. With its acidity and versatility, it  
could certainly be a strong candidate for future isosteric replacements.  
 
 
 
 
79 
 
 
                                                
 
 
Figure 88. Carboxylic acid to cyclopentane-1,3-dione substitution. The SMILES    
code transformation: OC=O>>O=C1CCC(O)=C1(*) 
 
 
SMIRKS:  
*C(=O)O>> O=C1CCC=(=O)C1 
 
 
Oxamate is an Alternative Substrate for Pyruvate Carboxylase from Rhizobium 
etli.66 
Oxamate is actively involved in the enzymatic decarboxylation of oxaloacetate in 
the pyruvate carboxylase domain. It has been shown to be isosterically and 
isoelectronically similar to pyruvate. The replacement of a methyl with a primary amino 
group has been shown to be an effective isosteric replacement. In this case, the remainder 
of the molecule is the same, aside from that change. Based upon the similar structures, 
masses, and sizes, these two compounds should be interchangeable in a number of 
situations. 
 
                                                      
 
Figure 89. Pyruvate to oxamate substitution. The SMILES code transformation:     
CC(=O)C(=O)[O-]>>[O-]C(=O)C(=O)N. 
 
 
SMIRKS: 
C[C:1](=O)[C:2](=O)[O-]>>[O-][C:1](=O)[C:2](=O)N 
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Dihydroorotase from the Hyperthermophile Aquifiex aeolicus is Activated by 
Stoichiometric Association with Aspartate Transcarbamoylase and Forms a One-
Pot Reactor for Pyrimidine Biosynthesis.67 
In mammals, pyrimidine biosynthesis is vital in cellular metabolism. Carbamoyl 
phosphate synthetase is one of the first three enzymes in this production. Citrate becomes 
attached in the course of this process. It is a near isosteric analogue of carbamoyl 
aspartate. In the transformation shown in Figure 90, the molecule’s shape has changed 
slightly, but the nitrogen atoms have been completely removed, with one hydroxyl group 
being added. 
 
  
Figure 90. Dicarbamoyl aspartate to citrate substitution. The SMILES code 
transformation: NC(CC(=O)OC(N)=O)C(=O)OC(N)=O>>C(C(=O)[O-])C(CC(=O)[O-
])(C(=O)[O-])O 
 
   SMIRKS:  
NC([C:1][C:2](=O)OC(N)=O)C(=O)OC(N)=O>>C(C(=O)[O-])C([C:1][C:2](=O)[O-
])(C(=O)[O-])O 
 
 
N-Hydroxypyrazolyl Glycine Derivatives as Selective N-Methyl-D-aspartic Acid 
Receptor Ligands.68  
A number of analogues were designed and produced utilizing N-hydroxypyrazole 
as a functional bioisostere for the distal carboxylate group on aspartate. Because so many 
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excitatory signals in the brain are influenced by glutamic acid through the glutamate 
receptors, there are many associated neurological problems. These include epilepsy, 
schizophrenia, and Alzheimer’s disease. With bioisosteric substitution, it is thought that 
improved selectivity can be achieved in neurotransmission. The substitution shown below 
could lead to improved selectivity in activation of NMDA receptors. In the 
transformation, an aromatic ring structure (pyrazol) has replaced the two oxygen atoms 
on the far right of the figure (See Figure 91). 
 
                                                            
Figure 91. Glutamic acid to amino(1-hydroxy-1H-pyrazol-4-yl)acetic acid 
substitution. The SMILES code transformation: 
C(CC(=O)O)C(C(=O)O)N>>c1c(cn(n1)O)C(C(=O)O)N. 
 
 
SMIRKS:  
C(CC(=O)O)[C]([C:1](=O)O)N>>N[C:1](C(=O)O)c1cn(O)nc1 
 
 
Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-
1 integrase inhibitors.69 
Virtual screening techniques were used to identify compounds capable of 
inhibiting HIV-1 integrase. The molecules shown below were attached to larger 
scaffoldings. These molecules were the portions that were actively substituted. In the 
transformation shown below, a six member closed ring was reduced to a five member 
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ring, a sulfur atom was substituted for a nitrogen atom, and an attached oxygen was 
removed. 
 
             
Figure 92. Thiobarbituric acid to rhodanine substitution.The parent compound is to 
the left. The SMILES code transformation: 
O=C1CC(=O)NC(=S)N1>>O=C1CSC(=S)N1. 
 
SMIRKS: 
[O:1]=[C:2]1CC(=O)NC(=S)N1>>[O:1]=[C:2]1CSC(=S)N1 
 
 
A Diverse Series of Substituted Benzenesulfonamides as Aldose Reductase 
Inhibitors with Antioxidant Activity: Design, Synthesis, and in Vitro Activity.70 
A phenosulfonamido acetic acid chemotype was determined to be an effective 
aldose reductase inhibitor. Replacement of the acetic acid with a difluorophenol exhibited 
potent antioxidant behavior. With the replacement of a small chain with a six member 
aromatic compound, selectivity could still an issue, so further adjustments need to be 
made. This could be a substitution that is limited by size issues and could only take place 
where plenty of room is available. 
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Figure 93. Benzenesulfonamide with substituted group indicated. 
 
 
                    
 
Figure 94. Acetic acid to 2,6-difluorophenol, with the attachment points shown with 
arrows. The SMILES code transformation: CC(=O)O>>c1(F)c(O)c(F)ccc1. 
 
 
SMIRKS:  
CC(=O)[O:1]>> c1(F)c([O:1])c(F)ccc1 
 
 
Ursodeoxycholic Acid Amides As Novel Glucocorticoid Receptor Modulators 71 
Ursodeoxycholic acid (UDCA) treats inflammatory diseases. Researchers tested 
UDCA derivatives to examine their effects on cancer lines. For this transformation, a 
hydroxyl group was replaced by an amide with a three member closed ring. 
 
                                      
         
 
Figure 95. UDCA with the substitution site indicated, followed by the transformation 
of acetic acid to N-cyclopropylacetamide. The SMILES code transformation: 
CC(=O)O>>CC(=O)NC1CC1. 
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SMIRKS: 
CC(=O)O>>CC(=O)NC1CC1 
 
            
Separation of Quercetin’s Biological Activity from Its Oxidative Property through 
Bioisosteric Replacement of the Catecholic Hydroxyl Groups with Fluorine Atoms.72    
Quercetin has been shown to have significant biologic activity due to its strong 
antioxidative properties. It is an abundant flavonoid, found in an abundance of foods. 
Oxidative damage is often associated with melanomas. The researchers wanted to isolate 
the various parts of quercetin by bioisosteric substitution. By doing this, they hope to 
figure out what specific part of the compound is responsible for the strong antioxidative 
state. A number of substitutions were tried in various parts of this large structure. In one 
successful bioisosteric substitution, two fluorine atoms replaced two hydroxides, giving 
the compound slightly more biological activity. 
 
                           
 
Figure 96. Quercetin to 3,4-difluoro-quercetin substitution. The SMILES code 
transformation: 
O=C1c3c(O/C(=C1/O)c2ccc(O)c(O)c2)cc(O)cc3O>>O=C1c3c(O/C(=C1/O)c2ccc(O)c(O
)c2)cc(F)cc3F. 
 
 
SMIRKS: 
[O:1]=[C:2]1[c:3]3[c:4](O/C(=C1/O)c2ccc(O)c(O)c2)cc(O)cc3O>> 
[O:1]=[C:2]1[c:3]3[c:4](O/C(=C1/O)c2ccc(O)c(O)c2)cc(F)cc3F 
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Inhibitors for Human Glutaminyl Cyclase by Structure Based Design and 
Bioisosteric Replacement.73 
Inhibition of human glutamyl cyclase (hQC) has been identified as a potential 
treatment for Alzheimer’s disease. A transformation of 1-(3,4-Dimethoxyphenyl)-3-[3-
(1H-imidazol-1-yl)propyl]thiourea to N-(3,4-dimethoxyphenyl)-1-[3-(1H-imidazol-1-
yl)propyl]cyclopropanecarbothioamide is shown to significantly increase inhibition, by a 
simple addition of a three carbon ring. 
     
 
 
 
 
  
 
Figure 97. 1-(3,4-Dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea to N-
(3,4-dimethoxyphenyl)-1-[3-(1H-imidazol-1-yl)propyl]cyclopropanecarbothioamide 
substitution. The SMILES code transformation: 
S=C(NCCCn1ccnc1)Nc2ccc(OC)c(OC)c2>>COc1ccc(cc1OC)NC(=S)C3(CCCn2ccnc2)
CC3. 
 
 
SMIRKS: 
[S:1]=[C:2](NCCCn1ccnc1)Nc2ccc(OC)c(OC)c2>>COc1ccc(cc1OC)N[C:2](=[S:1])C3(
CCCn2ccnc2)CC3 
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CHAPTER VII 
CONCLUSION 
 
 In the growing field of cheminformatics, utilizing computer software to facilitate 
pharmaceutical drug design is essential. The SMILES/SMIRKS coding (used in the Drug 
Guru program) is user friendly and offers many opportunities for additional software 
development. As more research efforts are directed toward the advancements of this drug 
design approach, the software will improve, the coding will become even simpler, and the 
ability of the software to eliminate unreasonable choices and to rank the transformations 
will make the system even more effective. 
 There were a number of new transformations presented in the previous pages. A 
number of the transformations are good for selective situations, while another quantity is 
more open to a larger scale. While some of the transformations may seem very selective, 
in fact they will become more usable as other connections are made. Consider two 
compounds that are related to each other structurally; when a third compound is found to 
have bioisosteric similarities to a compound, it may also become attached to the 
compound that was connected to it. These sorts of connections will keep the database 
growing constantly. A specific example is the transformation shown in Figure 29 earlier 
in the paper. This transformation could be called a carbonyl ene shift. In other words, 
when you have a conjugated enone system, the positions of the carbonyl and the double 
bond could be switched. This would take only a simple modification of the code
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The transformations presented in this thesis were numerous, but certainly not 
comprehensive. The Bowen research group in the Center for Drug Design at Mercer 
University College of Pharmacy will continue to investigate the possibilities for 
improvement in cheminformatics software and development. As more transformations are 
entered into the group’s database, the potential for bioisosteric substituents increases. This 
means that there could be theoretical an almost endless supply of bioisosteric 
transformations that could find their way into the database. So, while this is a conclusion 
to this thesis, it is only a small building block into the construction of a much larger future 
for drug design. 
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